A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-IIIA (1988) uterine papillary serous carcinoma of the endometrium

Gynecologic Oncology

Volumn 129, Issue 2, 2013, Pages 304-309

  Jhingran, Anuja ^a   Ramondetta, Lois M ^a   Bodurka, Diane C ^a   Slomovitz, Brian M ^b   Brown, Jubilee ^a   Levy, Lawrence B ^a   Garcia, Michael E ^a   Eifel, Patricia J ^a   Lu, Karen H ^a   Burke, Thomas W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MORRISTOWN MEMORIAL HOSPITAL   (United States)

Author keywords

Chemotherapy; Concurrent chemotherapy; Endometrial carcinoma; Papillary serous; Radiation therapy; Radiotherapy

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ABDOMINAL PAIN; ANOREXIA; ANXIETY; ARTICLE; BLOOD TOXICITY; BONE PAIN; BRACHYTHERAPY; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CHRONIC DIARRHEA; CONSTIPATION; DEHYDRATION; DESENSITIZATION; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENDOMETRIUM CARCINOMA; EXTERNAL BEAM RADIOTHERAPY; FATIGUE; FEMALE; FEVER; HEADACHE; HEARING DISORDER; HUMAN; INFECTION; INTENSITY MODULATED RADIATION THERAPY; LEUKOCYTE COUNT; LIVER FUNCTION TEST; MULTIPLE CYCLE TREATMENT; MYALGIA; MYLAGIA; NAUSEA; NEUROPATHY; NEUTROPENIA; NEUTROPHIL COUNT; OVERALL SURVIVAL; PELVIS FRACTURE; PHASE 2 CLINICAL TRIAL; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; RADIATION DOSE; RADIATION INJURY; RECTUM HEMORRHAGE; SARCOMA; SIDE EFFECT; SMALL INTESTINE OBSTRUCTION; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; SWEATING; THORAX PAIN; THROMBOCYTE; VAGINA; VOMITING;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BRACHYTHERAPY; CHEMORADIOTHERAPY, ADJUVANT; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, SEROUS; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYSTERECTOMY; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM STAGING; OVARIECTOMY; PACLITAXEL; PROSPECTIVE STUDIES; SALPINGECTOMY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84876297158     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2013.01.025     Document Type: Article

References (31)

1. W.T. Creasman, M.F. Kohler, F. Odicino, P. Maisonneuve, and P. Boyle Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium Gynecol Oncol 95 3 2004 593 596
2. W.K. Huh, M. Powell, C.A. Leath, J.M. Straughn, D.E. Cohn, and M.A. Gold Uterine papillary serous carcinoma: comparisons of outcomes in surgical stage I patients with and without adjuvant therapy Gynecol Oncol 91 3 2003 470 475
3. M.G. Kelly, D.M. O'Malley, P. Hui, J. McAlpine, H. Yu, and T.J. Rutherford Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy Gynecol Oncol 98 3 2005 353 359
4. J. Kwon, I. Ackerman, and E. Franssen The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma Int J Radiat Oncol Biol Phys 59 5 2004 1439 1445
5. B.M. Slomovitz, T.W. Burke, P.J. Eifel, L.M. Ramondetta, E.G. Silva, and A. Jhingran Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases Gynecol Oncol 91 3 2003 463 469
6. B.C. Turner, J.P. Knisely, B.M. Kacinski, B.G. Haffty, A.A. Gumbs, and K.B. Roberts Effective treatment of stage I uterine papillary serous carcinoma with high dose-rate vaginal apex radiation (192Ir) and chemotherapy Int J Radiat Oncol Biol Phys 40 1 1998 77 84
7. A.A. Martinez, S. Weiner, K. Podratz, A.R. Armin, J.S. Stromberg, and R. Stanhope Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation Gynecol Oncol 90 3 2003 537 546
8. J.T. Chambers, S.K. Chambers, E.I. Kohorn, M.L. Carcangiu, and P.E. Schwartz Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide Gynecol Oncol 60 3 1996 438 442
9. C. Levenback, T.W. Burke, E. Silva, M. Morris, D.M. Gershenson, and J.J. Kavanagh Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC) Gynecol Oncol 46 3 1992 317 321
10. F.V. Price, S.K. Chambers, M.L. Carcangiu, E.I. Kohorn, P.E. Schwartz, and J.T. Chambers Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC) Gynecol Oncol 51 3 1993 383 389
11. K.M. Zanotti, J.L. Belinson, A.W. Kennedy, K.D. Webster, and M. Markman The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma Gynecol Oncol 74 2 1999 272 277
12. L. Ramondetta, T.W. Burke, C. Levenback, M. Bevers, D. Bodurka-Bevers, and D. Gershenson Treatment of uterine papillary serous carcinoma with paclitaxel Gynecol Oncol 82 1 2001 156 161
13. J. Liebmann, J.A. Cook, J. Fisher, D. Teague, and J.B. Mitchell In vitro studies of Taxol as a radiation sensitizer in human tumor cells J Natl Cancer Inst 86 6 1994 441 446
14. R.B. Tishler, P.B. Schiff, C.R. Geard, and E.J. Hall Taxol: a novel radiation sensitizer Int J Radiat Oncol Biol Phys 22 3 1992 613 617
15. A.F. Wahl, K.L. Donaldson, C. Fairchild, F.Y. Lee, S.A. Foster, and G.W. Demers Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis Nat Med 2 1 1996 72 79
16. M.D. Chen, P.J. Paley, R.A. Potish, and L.B. Twiggs Phase I trial of Taxol as a radiation sensitizer with cisplatin in advanced cervical cancer Gynecol Oncol 67 2 1997 131 136
17. M.J. Glantz, H. Choy, W. Akerley, C.M. Kearns, M.J. Egorin, and C.H. Rhodes Weekly paclitaxel with and without concurrent radiation therapy: toxicity, pharmacokinetics, and response Semin Oncol 23 6 Suppl. 16 1996 128 135
18. H. Safran, T.P. King, H. Choy, P.J. Hesketh, B. Wolf, and E. Altenhein Paclitaxel and concurrent radiation for locally advanced pancreatic and gastric cancer: a phase I study J Clin Oncol 15 3 1997 901 907
19. J.H. Shepherd Revised FIGO staging for gynaecological cancer Br J Obstet Gynaecol 96 8 1989 889 892
20. A.N. Fader, R.D. Drake, D.M. O'Malley, H.E. Gibbons, W.K. Huh, and L.K. Havrilesky Platinum/taxane-based chemotherapy with or without radiation therapy favorably impacts survival outcomes in stage I uterine papillary serous carcinoma Cancer 115 10 2009 2119 2127
21. H. Goldberg, R.C. Miller, R. Abdah-Bortnyak, M. Steiner, F. Yildiz, and A. Meirovitz Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN) Gynecol Oncol 108 2 2008 298 305
22. A.N. Viswanathan, E.A. Macklin, R. Berkowitz, and U. Matulonis The importance of chemotherapy and radiation in uterine papillary serous carcinoma Gynecol Oncol. 123 3 2011 542 547
23. M.G. Kelly, D. O'Malley, P. Hui, J. McAlpine, J. Dziura, and T.J. Rutherford Patients with uterine papillary serous cancers may benefit from adjuvant platinum-based chemoradiation Gynecol Oncol 95 3 2004 469 473
24. F. Alongi, C. Fiorino, C. Cozzarini, S. Broggi, L. Perna, and G.M. Cattaneo IMRT significantly reduces acute toxicity of whole-pelvis irradiation in patients treated with post-operative adjuvant or salvage radiotherapy after radical prostatectomy Radiother Oncol 93 2 2009 207 212
25. S. Beriwal, S.K. Jain, D.E. Heron, H. Kim, K. Gerszten, and R.P. Edwards Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy Gynecol Oncol 102 2 2006 195 199
26. M.F. Chen, C.J. Tseng, C.C. Tseng, C.Y. Yu, C.T. Wu, and W.C. Chen Adjuvant concurrent chemoradiotherapy with intensity-modulated pelvic radiotherapy after surgery for high-risk, early stage cervical cancer patients Cancer J 14 3 2008 200 206
27. A.J. Mundt, A.E. Lujan, J. Rotmensch, S.E. Waggoner, S.D. Yamada, and G. Fleming Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies Int J Radiat Oncol Biol Phys 52 5 2002 1330 1337
28. A.J. Mundt, L.K. Mell, and J.C. Roeske Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy Int J Radiat Oncol Biol Phys 56 5 2003 1354 1360
29. J.C. Roeske, D. Bonita, L.K. Mell, A.E. Lujan, and A.J. Mundt A dosimetric analysis of acute gastrointestinal toxicity in women receiving intensity-modulated whole-pelvic radiation therapy Radiother Oncol 69 2 2003 201 207
30. R.A. Nout, V.T. Smit, H. Putter, I.M. Jurgenliemk-Schulz, J.J. Jobsen, and L.C. Lutgens Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial Lancet 375 9717 2010 816 823
31. B. DuBeshter, K. Estler, K. Altobelli, S. McDonald, C. Glantz, and C. Angel High-dose rate brachytherapy for stage I/II papillary serous or clear cell endometrial cancer Gynecol Oncol 94 2 2004 383 386